Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM

Beam Therapeutics

Beam Therapeutics patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2017
Employees
573
Programs
10
Drugs
14
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Beam Therapeutics patents

14 pharmaceutical patents indexed for Beam Therapeutics. 0 expire within 24 months.

Beam Therapeutics has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

14 patents

Patent portfolio

  1. US 12296053

    Nanomaterials comprising triols

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12268753

    Nanomaterials comprising a biodegradable feature

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12133884

    Methods of substituting pathogenic amino acids using programmable base editor systems

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12059477

    Nanomaterials

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11795443

    Uses of adenosine base editors

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11752202

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11594345

    Method for producing Ac-225 from Ra-226

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11344609

    Compositions and methods for treating hemoglobinopathies

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11155803

    Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11142760

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10919019

    Apparatus for the synthesis of radiopharmaceutical products

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10600528

    Process for producing Gallium-68 through the irradiation of a solution target

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8287819

    Device for synthesis of radiopharmaceutical products

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Beam Therapeutics have?

14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Beam Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.